<DOC>
	<DOC>NCT02635672</DOC>
	<brief_summary>Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BAY 1251152 in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).</brief_summary>
	<brief_title>Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Male or female patients aged &gt;18 years Patients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapies Adequate bone marrow, liver, and renal functions Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 Active clinically serious infections of &gt; Grade 2 Subjects who have new or progressive brain or meningeal or spinal metastases. Anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to the first dose of study drug Major surgery, significant trauma, widefield radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drug Allogenic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid tumors</keyword>
	<keyword>Aggressive non-hodgkin's lymphoma (NHL)</keyword>
</DOC>